{"hands_on_practices": [{"introduction": "A deep understanding of a pathogen begins with its metabolism—the biochemical engine that drives its survival and replication. *Treponema pallidum* is a prime example of metabolic specialization, having shed common pathways like the tricarboxylic acid (TCA) cycle and oxidative phosphorylation. This exercise challenges you to apply fundamental principles of biochemistry to quantify the energetic limitations of this unique spirochete, demonstrating how its dependence on host-derived molecules for ATP via glycolysis can be calculated from first principles. [@problem_id:4701540]", "problem": "Treponema pallidum, the causative agent of syphilis, has a streamlined metabolism and relies on carbohydrate catabolism for adenosine triphosphate (ATP) generation. Genomic and biochemical evidence indicate that Treponema pallidum lacks a complete tricarboxylic acid (TCA) cycle, an electron transport chain (ETC), and oxidative phosphorylation, but possesses the canonical Embden–Meyerhof–Parnas (EMP) glycolytic pathway enzymes necessary to convert glucose to pyruvate. For the purposes of this problem, assume the organism encodes and expresses the following glycolytic enzymes: hexokinase, phosphoglucose isomerase, phosphofructokinase, aldolase, triose phosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerate mutase, enolase, and pyruvate kinase. Also assume it encodes lactate dehydrogenase to reoxidize nicotinamide adenine dinucleotide (NADH) to nicotinamide adenine dinucleotide ($NAD^+$) by converting pyruvate to lactate. There is no acetate kinase or other fermentative route that generates ATP beyond glycolysis.\n\nStarting from fundamental definitions of substrate-level phosphorylation (enzyme-catalyzed transfer of a phosphate group to adenosine diphosphate (ADP) to form ATP, independent of a proton-motive force) and conservation of mass and redox equivalents across the EMP pathway with lactate fermentation to maintain redox balance, derive the maximum net yield of ATP per molecule of glucose that Treponema pallidum can produce solely via substrate-level phosphorylation under steady-state conditions where cytosolic inorganic phosphate, ADP, and NAD$^{+}$ are not limiting. Ignore any ATP costs or gains associated with transport processes or biosynthetic branch fluxes.\n\nExpress your final answer as a single real number representing the maximum count of ATP molecules generated per molecule of glucose via substrate-level phosphorylation. No rounding is required, and no units should be included in the final numerical answer.", "solution": "The organism lacks the tricarboxylic acid (TCA) cycle, an electron transport chain (ETC), and oxidative phosphorylation. Therefore, ATP can only be generated by substrate-level phosphorylation, which in glycolysis occurs at specific steps where a high-energy phosphate is transferred directly to adenosine diphosphate (ADP) to form adenosine triphosphate (ATP).\n\nWe begin from the canonical Embden–Meyerhof–Parnas (EMP) pathway stoichiometry for one molecule of glucose, under the assumption that all listed enzymes are present and functional:\n\n**Priming (investment) phase:**\n1. Hexokinase: $$\\text{glucose} + \\text{ATP} \\rightarrow \\text{glucose-6-phosphate} + \\text{ADP}$$ This consumes $1$ ATP.\n2. Phosphofructokinase: $$\\text{fructose-6-phosphate} + \\text{ATP} \\rightarrow \\text{fructose-1,6-bisphosphate} + \\text{ADP}$$ This consumes $1$ ATP.\n\nAt this point, a total of $2$ ATP have been consumed.\n\n**Splitting and oxidation:**\n3. Aldolase and triose phosphate isomerase convert fructose-1,6-bisphosphate to two molecules of glyceraldehyde-3-phosphate (G3P).\n4. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for each G3P:\n$$\\text{G3P} + \\text{P}_{\\mathrm{i}} + NAD^+ \\rightarrow 1,3\\text{-bisphosphoglycerate} + \\text{NADH} + \\text{H}^+$$\nThis step produces no ATP directly but generates $1$ NADH per G3P, i.e., $2$ NADH per glucose.\n\n**Payoff (ATP-generating) phase via substrate-level phosphorylation:**\n5. Phosphoglycerate kinase (PGK) for each 1,3-bisphosphoglycerate:\n$$1,3\\text{-bisphosphoglycerate} + \\text{ADP} \\rightarrow 3\\text{-phosphoglycerate} + \\text{ATP}$$\nThis produces $1$ ATP per G3P, i.e., $2$ ATP per glucose.\n6. Pyruvate kinase (PK) for each phosphoenolpyruvate (PEP):\n$$\\text{PEP} + \\text{ADP} \\rightarrow \\text{pyruvate} + \\text{ATP}$$\nThis produces $1$ ATP per G3P, i.e., $2$ ATP per glucose.\n\nSumming substrate-level phosphorylation in the payoff phase yields $4$ ATP produced per glucose ($2$ at the phosphoglycerate kinase step and $2$ at the pyruvate kinase step). Summing ATP consumption in the priming phase yields $2$ ATP consumed per glucose. Therefore, the net ATP from glycolysis via substrate-level phosphorylation is:\n$$\\text{net ATP} = 4 - 2 = 2.$$\n\nRedox balance must be maintained because glyceraldehyde-3-phosphate dehydrogenase produces $2$ NADH per glucose. In the absence of oxidative phosphorylation and an electron transport chain, reoxidation of NADH to NAD$^{+}$ must occur through fermentation. With lactate dehydrogenase present, the reaction\n$$\\text{pyruvate} + \\text{NADH} + \\text{H}^{+} \\rightarrow \\text{lactate} + NAD^+$$\nconsumes the $2$ NADH generated and regenerates $2$ NAD$^{+}$, allowing the GAPDH step to proceed at steady state. This fermentation step does not generate ATP. Furthermore, we have stipulated absence of acetate kinase or other ATP-yielding fermentative routes; thus, no additional substrate-level phosphorylation occurs beyond the glycolytic phosphoglycerate kinase and pyruvate kinase steps.\n\nUnder these constraints, and ignoring any transport or biosynthetic ATP costs, the maximum net ATP yield per molecule of glucose via substrate-level phosphorylation is therefore $2$.", "answer": "$$\\boxed{2}$$", "id": "4701540"}, {"introduction": "Effective antimicrobial therapy halts pathogen replication, but how do we quantitatively measure treatment success? For syphilis, this is accomplished by monitoring the decay of the host's non-treponemal antibody response over time. This practice bridges the gap between immunology and clinical practice by modeling antibody clearance as a first-order kinetic process, allowing you to translate the clinically accepted benchmark for serologic cure—a fourfold titer decline—into a quantitative mathematical framework. [@problem_id:4701525]", "problem": "A patient with early syphilis receives appropriate intramuscular benzathine penicillin G at time $t=0$, with a baseline non-treponemal Rapid Plasma Reagin (RPR) titer of $1:32$. Non-treponemal titers are measured by serial twofold dilutions, so each one-step change corresponds to a factor of $2$. After effective therapy and elimination of Treponema pallidum, the antigenic stimulus ceases and the non-treponemal antibody concentration is expected to decline as the immune response contracts. Assume the post-clearance decay of the non-treponemal antibody concentration is governed by first-order kinetics. Using the definitions of first-order decay and the twofold dilution structure of non-treponemal titers, derive the range of the first-order rate constant $k$ (in units of per month) that is consistent with observing a fourfold ($4$-fold) decline in RPR titer between $t=6$ months and $t=12$ months. Based on these principles and clinically accepted follow-up for early syphilis, choose the option that correctly states both the derived range for $k$ and appropriate criteria for defining serologic cure versus the serofast state in early syphilis.\n\nA. A fourfold decline corresponds to two dilution steps ($2$ steps, factor $2^2=4$). For first-order decay, the required rate constant satisfies $k \\in \\left[\\dfrac{\\ln 4}{12}, \\dfrac{\\ln 4}{6}\\right]$ per month. Serologic cure is defined as either a decline of at least $4$-fold in non-treponemal titer by $t=6$–$12$ months compared with baseline (for example, from $1:32$ to $\\leq 1:8$), or reversion to nonreactive; the serofast state is defined as persistently reactive non-treponemal titers at low level (typically $\\leq 1:8$) without achieving a $4$-fold decline by $t=12$ months, with stability within $\\pm 1$ dilution, absence of clinical signs, and no evidence of neurosyphilis on cerebrospinal fluid (CSF) evaluation when indicated.\n\nB. A fourfold decline is expected within $t=2$ months, so $k=\\dfrac{\\ln 4}{2}$ per month. Serologic cure is defined by nonreactivity of a treponemal test (for example, fluorescent treponemal antibody-absorption) by $t=6$ months, and the serofast state is defined by persistent treponemal test reactivity without regard to non-treponemal titers.\n\nC. Because immunoglobulin G (IgG) has a half-life of approximately $21$ days, non-treponemal titers should decline eightfold ($8$-fold) by $t=6$–$12$ months, implying $k \\in \\left[\\dfrac{\\ln 8}{12}, \\dfrac{\\ln 8}{6}\\right]$ per month. Serologic cure requires treponemal test titers to normalize, while the serofast state is identified by any residual nonreactivity on treponemal testing.\n\nD. A clinically meaningful decline is one dilution step ($2$-fold), so $k \\in \\left[\\dfrac{\\ln 2}{12}, \\dfrac{\\ln 2}{6}\\right]$ per month. Serologic cure is defined by a $2$-fold decline at $t=6$ months, and the serofast state is defined as a titer $\\leq 1:2$ at $t=12$ months regardless of trajectory or clinical assessment.", "solution": "**1. Mathematical Derivation of the Rate Constant ($k$)**\nThe decay of antibody concentration $C(t)$ follows first-order kinetics: $C(t) = C(0)e^{-kt}$. A fourfold decline from the baseline concentration $C(0)$ means $C(t) \\le \\frac{1}{4}C(0)$.\n\nThe problem states this decline should occur between 6 and 12 months post-treatment.\n- To achieve the decline by the *latest* acceptable time, $t=12$ months, the rate constant $k$ must be large enough that $C(12) \\le \\frac{1}{4}C(0)$. This leads to the inequality $e^{-12k} \\le \\frac{1}{4}$, which simplifies to $k \\ge \\frac{\\ln 4}{12}$. This establishes the lower bound for $k$.\n- The decline should occur at or *after* $t=6$ months. The boundary condition is achieving the decline exactly at $t=6$ months, which gives $C(6) = \\frac{1}{4}C(0)$, or $e^{-6k} = \\frac{1}{4}$. This simplifies to $k = \\frac{\\ln 4}{6}$, establishing the upper bound for $k$.\n\nCombining these, the valid range for the rate constant is $k \\in \\left[\\frac{\\ln 4}{12}, \\frac{\\ln 4}{6}\\right]$ per month.\n\n**2. Analysis of Clinical Definitions and Options**\n- **Option A:** The calculated range for $k$ matches our derivation. The clinical definitions are correct: a fourfold decline in non-treponemal titer (e.g., from 1:32 to $\\le 1:8$) by 6–12 months defines serologic cure (an adequate response). The serofast state is correctly defined as the failure to achieve this decline, resulting in a persistent low-level reactive titer, after excluding other possibilities like reinfection or neurosyphilis.\n- **Option B:** Incorrect. Serologic cure is monitored with non-treponemal tests, not treponemal tests (like FTA-ABS), which usually remain positive for life. The time frame is also incorrect.\n- **Option C:** Incorrect. The clinical standard is a fourfold, not an eightfold, decline. It also incorrectly uses treponemal tests to define cure.\n- **Option D:** Incorrect. A clinically significant response is a fourfold (two-dilution), not a twofold (one-dilution), decline. The definition of the serofast state is also imprecise and incomplete.\n\nTherefore, option A provides both the correct mathematical range and the accurate clinical definitions.", "answer": "$$\\boxed{A}$$", "id": "4701525"}, {"introduction": "Clinical decision-making in infectious diseases often involves navigating a landscape of diagnostic uncertainty, especially in complex cases like neurosyphilis in an immunocompromised host. This advanced practice introduces the power of Bayesian reasoning to synthesize multiple, sometimes conflicting, pieces of diagnostic evidence. By applying Bayes' theorem, you will learn to formally update the probability of disease in a realistic clinical scenario, directly linking a quantitative posterior probability to a critical treatment threshold. [@problem_id:4701541]", "problem": "A Human Immunodeficiency Virus (HIV)-infected adult with symptomatic syphilis completed a standard course of aqueous crystalline penicillin G. At a 3-month reassessment for possible neurosyphilis, cerebrospinal fluid (CSF) testing shows a mixture of positive and negative results. You are asked to update the probability of active neurosyphilis using Bayes’ theorem, starting from first principles and using test characteristics grounded in the literature for HIV-coinfected individuals. Assume that, conditional on true disease status, the following CSF tests are independent.\n\nBaseline pretest probability of active neurosyphilis: $0.30$.\n\nObserved CSF results with corresponding test characteristics in HIV-coinfected patients:\n- CSF Venereal Disease Research Laboratory (VDRL): negative. Sensitivity $0.70$, specificity $0.98$.\n- CSF fluorescent treponemal antibody-absorption (FTA-ABS): positive. Sensitivity $0.95$, specificity $0.75$.\n- CSF pleocytosis defined as CSF white blood cell count $> 20\\ \\text{cells}/\\mu\\text{L}$: positive. Sensitivity $0.80$, specificity $0.60$.\n\nInstitutional decision protocol: extend or retreat neurosyphilis therapy if the updated (posterior) probability of active neurosyphilis is at least $0.40$.\n\nUsing Bayes’ theorem and the definition of likelihood ratios derived from sensitivity and specificity, compute the posterior probability of active neurosyphilis after observing these CSF results. Then, determine whether the institutional threshold for extended therapy is met. Express the posterior probability as a decimal fraction with no unit, rounded to three significant figures. Your final numeric answer should be the posterior probability only.", "solution": "The problem requires calculating the posterior probability of active neurosyphilis using Bayes' theorem, preferably in its odds-likelihood ratio form for handling multiple independent tests.\n\nLet $NS$ be the event of active neurosyphilis. The pretest probability is $P(NS) = 0.30$.\nThe pretest odds are calculated as:\n$$ \\text{Pretest Odds} = \\frac{P(NS)}{1 - P(NS)} = \\frac{0.30}{1 - 0.30} = \\frac{0.30}{0.70} = \\frac{3}{7} $$\n\nNext, we calculate the likelihood ratio (LR) for each of the three independent test results.\nThe likelihood ratio for a positive test is $LR(+) = \\frac{\\text{Sensitivity}}{1 - \\text{Specificity}}$.\nThe likelihood ratio for a negative test is $LR(-) = \\frac{1 - \\text{Sensitivity}}{\\text{Specificity}}$.\n\n1.  **CSF VDRL (negative):**\n    Sensitivity $S_1 = 0.70$; Specificity $Sp_1 = 0.98$.\n    $$ LR_1 = LR(-) = \\frac{1 - 0.70}{0.98} = \\frac{0.30}{0.98} $$\n\n2.  **CSF FTA-ABS (positive):**\n    Sensitivity $S_2 = 0.95$; Specificity $Sp_2 = 0.75$.\n    $$ LR_2 = LR(+) = \\frac{0.95}{1 - 0.75} = \\frac{0.95}{0.25} $$\n\n3.  **CSF pleocytosis (positive):**\n    Sensitivity $S_3 = 0.80$; Specificity $Sp_3 = 0.60$.\n    $$ LR_3 = LR(+) = \\frac{0.80}{1 - 0.60} = \\frac{0.80}{0.40} $$\n\nThe combined likelihood ratio ($LR_{combined}$) is the product of the individual LRs:\n$$ LR_{combined} = LR_1 \\times LR_2 \\times LR_3 = \\left(\\frac{0.30}{0.98}\\right) \\times \\left(\\frac{0.95}{0.25}\\right) \\times \\left(\\frac{0.80}{0.40}\\right) $$\n$$ LR_{combined} = \\left(\\frac{30}{98}\\right) \\times \\left(\\frac{95}{25}\\right) \\times (2) = \\frac{114}{49} $$\n\nNow, we update the pretest odds to get the posterior odds:\n$$ \\text{Posterior Odds} = \\text{Pretest Odds} \\times LR_{combined} $$\n$$ \\text{Posterior Odds} = \\frac{3}{7} \\times \\frac{114}{49} = \\frac{342}{343} $$\n\nFinally, we convert the posterior odds back to a probability:\n$$ \\text{Posterior Probability} = \\frac{\\text{Posterior Odds}}{1 + \\text{Posterior Odds}} $$\n$$ P(NS | \\text{Evidence}) = \\frac{342/343}{1 + 342/343} = \\frac{342/343}{685/343} = \\frac{342}{685} $$\n\nCalculating the decimal value and rounding to three significant figures:\n$$ \\frac{342}{685} \\approx 0.49927... \\approx 0.499 $$\n\nThe calculated posterior probability of $0.499$ is greater than the institutional threshold of $0.40$, so the condition for extending therapy is met. The problem asks for the posterior probability itself.", "answer": "$$\\boxed{0.499}$$", "id": "4701541"}]}